ArticleCommunications medicine2026
Reconstructing the pharmacogenomic landscape of psychiatric medication metabolism in the Indian population.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reconstructing the pharmacogenomic landscape of psychiatric medication metabolism in the Indian population.Communications medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the advent of genomic technologies, pharmacogenomics has evolved significantly. Such advancement facilitates comprehensive identification of common and rare alleles crucial for psychiatry treatments, especially in context of Indian psychiatric patients who are genetically diverse and for whom data is limited.
methodsThis study explores the pharmacogenomic spectrum of CYP2C19, CYP2D6, and CYP2C9 genes in an Indian psychiatric cohort of 383 individuals (264 patients, 119 controls) using Axiom PMD Array.
resultsBeyond common phenotypes like CYP2C19 *1/*2, we identified rare functional phenotypes including CYP2C19 *1/*34, CYP2C9 *1/*11 and CYP2D6 *4/*5 that are frequently overlooked in regular screenings. Interestingly, 3% of individuals were identified as most likely non-responders to medications metabolized by these three enzymes, suggesting the importance of platforms that cover both common and rare alleles in populations with high diversity. The study observed 13.26% poor CYP2C19 metabolizers, 2.27% poor CYP2D6 metabolizers, and 3.41% poor CYP2C9 metabolizers in the psychiatric cohort.
conclusionsThe study identifies three percent of the cohort shows compromised metabolism across all three genes, emphasizing that comprehensive screening of common along with rare functional variants is essential for personalized psychiatric treatment in India.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.